Update on the Role of FeNO in Asthma Management

Authors

Neveda Murugesan
Damini Saxena
Arundhati Dileep
Muhammad Adrish
Nicola A Hanania

Publication Date

4-15-2023

Journal

Diagnostics

DOI

10.3390/diagnostics13081428

PMID

37189529

PMCID

PMC10137365

PubMedCentral® Posted Date

4-15-2023

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Keywords

fractional excretion of nitric oxide, FeNO, asthma, outcomes

Abstract

Asthma is a heterogenous disorder characterized by presence of different phenotypes and endotypes. Up to 10% of the individuals suffer from severe asthma and are at increased risk of morbidity and mortality. Fractional exhaled nitric oxide (FeNO) is a cost-effective, point of care biomarker that is used to detect type 2 airway inflammation. Guidelines have proposed to measure FeNO as an adjunct to diagnostic evaluation in individuals with suspected asthma and to monitor airway inflammation. FeNO has lower sensitivity, suggesting that it may not be a good biomarker to rule out asthma. FeNO may also be used to predict response to inhaled corticosteroids, predict adherence and deciding on biologic therapy. Higher levels of FeNO have been associated with lower lung function and increased risk for future asthma exacerbations and its predictive value increases when combined with other standard measurements of asthma assessment.

Comments

Associated Data